The current way of diagnosing type-2 diabetes using blood glucose levels needs to be revised, research by scientists from The University of Manchester and King’s College London suggests. The findings, published in the journal PLOS ONE, show the current method of diagnosis - using blood glucose levels - means patients are diagnosed too late so that their blood vessels may already be damaged.
Type 2 diabetes, which affects over 90% of all adults with diabetes, often leads to heart damage and blood vessel problems in the brain, eyes and kidneys. It is closely linked to increasing levels of obesity, lack of exercise, unhealthy diets and our aging population.
The study focused on young, previously pregnant women followed up in Greater Manchester after being identified as at increased, intermediate and low risk of developing type-2 diabetes. Researchers examined biochemical markers in the blood before glucose became elevated – so before the patients reached the pre-diabetes stage.
Their findings show that changes in types of blood fat metabolites - naturally occurring particles that come from and make up fats in the blood - appear to be good indicators of developing type-2 diabetes. The changes in these particles were detectable well before changes in blood glucose that now define type-2 diabetes or pre-diabetes.
Professor Kennedy Cruickshank, lead author of the study and Professor of Cardiovascular Medicine and Diabetes in the Division of Diabetes & Nutritional Sciences at King’s College London (formerly at The University of Manchester) said his team’s findings could be important for future diagnosis and, in turn, treatments.
Professor Cruickshank said: “We found that several groups of fat metabolites, also linked to body fat, were changed in the blood, as were others including some amino acids and to some extent vitamin D, before glucose levels increased. Blood vessels become damaged as part of the condition, but problems in the vessels arise before high blood sugar sets in during a ‘pre-diabetes’ period.
“The current method of categorising type-2 diabetes solely by a patient’s glucose level means that many will already have suffered blood vessel damage and will experience poorer outcomes. Our study overall adds weight to the argument that type-2 diabetes should not be classified as ‘diabetes’ as we currently understand it from just measuring blood glucose.”
The authors argue that rather than concentrating purely on glucose-directed treatments, which do not improve blood vessel health, a new, quite different definition of type-2 diabetes is required, partly based on the distribution of fat metabolites in the blood in the pre-diabetes stage.
Dr Simon Anderson, co-author of the study and National Institute for Health Research Clinical Lecturer in Cardiology from The University of Manchester, said: “This long-term study of women in Greater Manchester adds to growing evidence about the major role that fats and fat metabolites play in the health of blood vessels, and in diabetes per se. To help clarify the metabolic conditions that lead to the development of type-2 diabetes, further assessment of the total chemicals in the blood – the metabolome - is necessary.
“In the long-term we aim to identify a biomarker or a disorder in a chemical pathway that is linked to blood vessel health and subsequent diabetes. Ultimately this might translate into a specific blood test to identify people at risk of type-2 diabetes early on but most importantly, it may allow advice on lifestyle modification at an earlier stage to reduce the long-term impact of diabetes.”
The team say more work is now needed to validate this alternative approach to diagnosing, treating and preventing diabetes.
Work is now ongoing at King’s to establish earlier treatments for blood vessels and the heart in people at risk of diabetes, while researchers in Manchester are looking at the risk of developing diabetes for children born from mothers with gestational diabetes and varying degrees of fatness.
The University of Manchester, a member of the prestigious Russell Group of British universities, is the largest and most popular university in the UK. It has 20 academic schools and hundreds of specialist research groups undertaking pioneering multi-disciplinary teaching and research of worldwide significance. According to the results of the 2008 Research Assessment Exercise, The University of Manchester is one of the country’s major research institutions, rated third in the UK in terms of ‘research power’, and has had no fewer than 25 Nobel laureates either work or study there. The University had an annual income of £807 million in 2011/12.
The National Institute for Health Research (NIHR) is funded by the Department of Health to improve the health and wealth of the nation through research. Since its establishment in April 2006, the NIHR has transformed research in the NHS. It has increased the volume of applied health research for the benefit of patients and the public, driven faster translation of basic science discoveries into tangible benefits for patients and the economy, and developed and supported the people who conduct and contribute to applied health research. The NIHR plays a key role in the Government’s strategy for economic growth, attracting investment by the life-sciences industries through its world-class infrastructure for health research. Together, the NIHR people, programmes, centres of excellence and systems represent the most integrated health research system in the world. For further information, visit the NIHR website (www.nihr.ac.uk).